Peptides DB
Research-centric peptide and protocol reference hub
Study 16 of 18Vosoritide literatureCalcified tissue international · Observational2022

Guanylyl Cyclase-B Dependent Bone Formation in Mice is Associated with Youth, Increased Osteoblasts, and Decreased Osteoclasts.

Vosoritide treatment in mice increased osteoblast levels and altered bone-related mRNA expression, but did not enhance mineral apposition rates.

Read at Calcified tissue internationalAdd to compare

Where it sits

this study against the rest of the vosoritide corpus
1
Preclinical
13
Observational · this one
0
Open-label
1
Randomised
3
Reviews

Summary and findings

This study investigated the effects of Vosoritide on bone formation in mice, specifically examining changes in osteoblast and osteoclast levels. The treatment was administered to 12-week-old wild type mice for 28 days. Results indicated changes in bone mass and cellular activity, but specific effects on mineral apposition rates were not observed.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Sclerostin mRNA was elevated 400-fold.2022

Abstract

The authors’ words, as Calcified tissue international supplied them

C-type natriuretic peptide (CNP) activation of guanylyl cyclase-B (GC-B) catalyzes the synthesis of cGMP in chondrocytes and osteoblasts. Elevated cGMP stimulates long bone growth, and inactivating mutations in CNP or GC-B reduce cGMP, which causes dwarfism. GC-B<sup>7E/7E</sup> mice that express a GC-B mutant that cannot be inactivated by dephosphorylation exhibit increased CNP-dependent GC-B activity, which increases bone length, as well as bone mass and strength. Importantly, how GC-B increases bone mass is not known. Here, we injected 12-week-old, wild type mice once daily for 28 days with or without BMN-111 (Vosoritide), a proteolytically resistant CNP analog. We found that BMN-111 treated mice had elevated levels of osteocalcin and collagen 1 C-terminal telopeptide (CTX) as well as increased osteoblasts and osteoclasts. In BMN-111 injected mice, tibial mRNAs for Rank ligand and osteoprotegrin were increased and decreased, respectively, whereas sclerostin mRNA was elevated 400-fold, consistent with increased osteoclast activity and decreased osteoblast activity. Mineral apposition rates and trabecular bone mass were not elevated in response to BMN-111. Because 9-week-old male GC-B<sup>7E/7E</sup> mice have increased bone mass but do not exhibit increased mineral apposition rates, we examined 4-week-old male GC-B<sup>7E/7E</sup> mice and found that these animals had increased serum osteocalcin, but not CTX. Importantly, tibias from these mice had 37% more osteoblasts, 26% fewer osteoclasts as well as 36% and 40% higher mineral apposition and bone formation rates, respectively. We conclude that GC-B-dependent bone formation is coupled to an early juvenile process that requires both increased osteoblasts and decreased osteoclasts.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Not reported in abstract.
  • Not reported in abstract.
  • Not reported in abstract.

Limitations

  • Not reported in abstract.
  • Not reported in abstract.

Elsewhere in the Vosoritide corpus

CC-type natriuretic peptide analog treatment of craniosynostosis in a Crouzon syndrome mouse model.PloS one · 2018 · Not reported in abstract.AnimalCPhosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth.JCI insight · 2021 · Not reported in abstract.AnimalAA phase II basket trial of vosoritide in children with RASopathies, ACAN, and NPR2 deficiency.The Journal of clinical endocrinology and metabolism · 2023 · n=30 · AGV increased from 4.53 ± 1.61 cm/year to 8.09 ± 1.58 cm/year with treatment (P < .0001).HumanDPremarket and postmarket real-world evidence studies supporting U.S. Food and Drug Administration regulatory decision-making, 2016-2024.Clinical trials (London, England) · 2026 · 43 (10.8%) had at least one real-world evidence study supporting premarket determinations.reviewCThe phosphatase inhibitor LB-100 acts synergistically with the NPR2 agonist BMN-111 to improve bone growthbiorxiv-preprint · 2020 · ∼25% increase in femur growth vs BMN-111 alone.AnimalDEfficacy and Safety of Vosoritide for Achondroplasia: A Systematic Review and Dose- Related Meta-Analysis, 2024 Article type: Systematic review and Dose-related Meta-analysisbiorxiv-preprint · 2024 · Higher vosoritide doses (15 µg/kg or 15–30 µg/kg) showed significantly greater improvements in height z-scores compared to lower doses (2.5 µg/kg or 7.5 µg/kg) or placebo.review